Abstract:Background: Meningococcal septic shock in children results in high mortality and morbidity, and decreased protein C levels in these patients are associated with a poor outcome. We carried out a randomized, double-blinded, placebo-controlled study by supplying protein C concentrate. This phase 2 study was designed to assess the activation process of protein C and to study the dosing regimen of protein C concentrate in children with purpura fulminans and meningococcal septic shock in the perspective of a possible phase 3 trial. Methods: Forty children were randomized to receive placebo or protein C concentrate (200 IU/kg, 400 IU/kg, or 600 IU/kg), for a maximum of 7 days. Clinical and laboratory data, including plasma levels of protein C and activated protein C (APC), were collected at various time points. All patients received standard therapy for septic shock, including antibiotics, inotropic/vasoactive drugs, and blood products. Results: Increased APC levels relative to baseline were observed for the 27 of 28 patients treated with protein C concentrate, and the areas under the curve of protein C and APC were correlated with the dosage of protein C concentrate administered. Activation of coagulation, as evidenced by d-dimer levels, as well as the ratio of thrombin vs. APC normalized significantly faster with increasing dosages of protein C concentrate. No adverse reactions related to protein C concentrate were observed. Nine of the 40 (23%) patients died, and five survivors required amputations, with no differences in these rates among the randomized groups. Baseline APC levels were positively correlated with sequential organ failure assessment and pediatric risk of mortality scores and with d-dimers, tumor necrosis factor-alpha, interleukin-1, interleukin-6, interleukin-8, plasminogen activator inhibitor-1, TAT complexes, and PAP complexes. Conclusions: Treatment with protein C concentrate is safe in children with purpura fulminans and meningococcal septic shock and leads to dose-related increases of plasma APC and resolution of coagulation imbalances.

Severe Congenital Protein C Deficiency: Practical Aspects of Management

Comprehensive literature review of protein C concentrate use in patients with severe congenital protein C deficiency

Management of severe congenital protein C deficiency with a direct oral anticoagulant, edoxaban: A case report

Use of protein C concentrate in pediatric patients with sepsis

Clinical and genetic features of Chinese pediatric patients with severe congenital protein C deficiency who first presented with purpura fulminans: A case series study and literature review

An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia

Genotypic and phenotypic character of Chinese neonates with congenital protein C deficiency: a case report and literature review

Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease

Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice

Clinical implications of genetic testing for congenital protein C deficiency in pregnancy

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study

A Review of Research on Inherited Protein C Deficiency Syndrome

Unraveling the Molecular Pathogenesis of Protein C Deficiency-Associated VTE: Insights from Protein C Mutations C238G and R189W in Thai Patients

Hereditary Protein C Deficiency Caused by Compound Heterozygous Mutants in Two Independent Chinese Families

Protein C Thr315Ala Variant Results in Gain of Function but Manifests As Type II Deficiency in Diagnostic Assays.

A case of purpura fulminans secondary to transient protein C deficiency as a complication of chickenpox infection

Anticoagulant effects of protein C, protein S, and antithrombin levels on the protein C pathway in young children

Homozygous Protein C Deficiency with Late Onset Venous Thrombosis: Identification and in Vitro Expression Study of a Novel Pro275Ser Mutation.

Treatment of purpura fulminans in meningococcemia with protein C concentrate

Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis

Severe Protein C Deficiency due to Novel Biallelic Variants in PROC and Their Phenotype Correlation